John Adams, DO
General Practice · Plain City, OHNPI 1487603601
Payments from drug & device makers
Across 170 payments — averaging $12.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$804
- Novo Nordisk$219
- Amarin Pharma, Inc.$139
- AstraZeneca$137
- Merck$96
- Astellas Pharma US Inc$93
- plus $639 from 17 others
What the payments were for
- Food & beverage$2,06597%
- Education$623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $804 |
| Novo Nordisk | 22 | $219 |
| Amarin Pharma, Inc. | 8 | $139 |
| AstraZeneca | 10 | $137 |
| Merck | 6 | $96 |
| Astellas Pharma US Inc | 3 | $93 |
| Pfizer | 6 | $84 |
| Lilly USA, LLC | 5 | $81 |
| Johnson & Johnson | 4 | $63 |
| Phathom Pharmaceuticals, Inc. | 2 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Inspire Medical Systems, Inc. | 1 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $38 |
| Corcept Therapeutics | 2 | $33 |
| Boehringer Ingelheim | 2 | $29 |
| GSK | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Amgen | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
How this compares
$2,127 in reported general payments places this provider in the 90th percentile of 2,933 general practice providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 111 | $88,038 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $47,980 |
| JanuviaSitagliptin Phosphate | 38 | $33,435 |
| JardianceEmpagliflozin | 24 | $27,093 |
| MyrbetriqMirabegron | 50 | $24,738 |
| XareltoRivaroxaban | 24 | $21,346 |
| LinzessLinaclotide | 31 | $16,899 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $16,808 |
| TradjentaLinagliptin | 21 | $12,472 |
| InvokanaCanagliflozin | 16 | $12,454 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,360 |
| VascepaIcosapent Ethyl | 19 | $10,526 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 20 | $6,263 |
| Celecoxib | 45 | $6,239 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $84 | $94,300131 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $25 | $60,34192 claims |
| Boehringer IngelheimJardiance, Tradjenta | $29 | $39,56545 claims |
| Johnson & JohnsonXarelto, Invokana | $63 | $33,80040 claims |
| MerckJanuvia | $96 | $33,43538 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $24,73850 claims |
| AbbVieLinzess, Synthroid | $804 | $19,41774 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $19 | $5,79613 claims |
| AstraZenecaBrilinta | $137 | $5,52712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,933 general practice providers in Ohio.
Other general practice in Plain City
- Corey RaymondSalem$288K
- Luiz MeirellesColumbus$229K
- Heather PetroffBroadview Heights$170K
- William HuntzingerSylvania$102K
- Megan WeisenbergerCincinnati$81K
- Lundon AlbrechtMentor$77K
- Daniel WardColumbus$68K
- Ankur GuptaNorth Ridgeville$67K
- Maria Bermudez-FresseOakwood$65K
- Jill BartonCanfield$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.